Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Drug Design, Development and Therapy|March 3, 2018
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancerSilvia Paola Corona, Daniele Generali
Medical Oncology (Northwood, London, England)|August 31, 2017
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysisGiandomenico Roviello, Silvia Paola Corona, Daniele Generali
Therapeutic Advances in Medical Oncology|August 21, 2019
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?Giandomenico Roviello, Silvia Paola Corona, Gabriella Nesi, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 9, 2019
Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After ChemotherapyGiandomenico Roviello, Silvia Paola Corona, Michele Aieta, et al.
International Journal of Clinical Oncology|November 10, 2019
Corticosteroid switch after progression on abiraterone acetate plus prednisoneGiandomenico Roviello, Navid Sobhani, Silvia Paola Corona, et al.
Oncotargets and Therapy|August 18, 2017
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancerGiandomenico Roviello, Silvia Paola Corona, Alberto Bonetta, et al.
Molecular & Cellular Oncology|September 18, 2020
Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patientsRaheleh Roudi, Mahboubeh Barodabi, Zahra Madjd, et al.
International Journal of Molecular Sciences|January 16, 2020
Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-AnalysisGiandomenico Roviello, Silvia Paola Corona, Alberto D'Angelo, et al.
Cancer Medicine|March 18, 2022
Dual drug targeting to kill colon cancersSilvia Paola Corona, Francesca Walker, Janet Weinstock, et al.
Medicine|July 3, 2019
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?Giandomenico Roviello, Silvia Paola Corona, Raffaele Conca, et al.
Pageof 3